Mebutamate

Chemical compound
  • N05BC04 (WHO)
Legal statusLegal status Identifiers
  • 2-sec-Butyl-2-methylpropane-1,3-diyl dicarbamate
CAS Number
  • 64-55-1 ☒N
PubChem CID
  • 6151
ChemSpider
  • 5919 ☒N
UNII
  • 5H8F175RER
KEGG
  • D01807 checkY
ChEMBL
  • ChEMBL1200922 ☒N
CompTox Dashboard (EPA)
  • DTXSID1023239 Edit this at Wikidata
ECHA InfoCard100.000.534 Edit this at WikidataChemical and physical dataFormulaC10H20N2O4Molar mass232.280 g·mol−13D model (JSmol)
  • Interactive image
  • CCC(C)C(C)(COC(=O)N)COC(=O)N
InChI
  • InChI=1S/C10H20N2O4/c1-4-7(2)10(3,5-15-8(11)13)6-16-9(12)14/h7H,4-6H2,1-3H3,(H2,11,13)(H2,12,14) ☒N
  • Key:LEROTMJVBFSIMP-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Mebutamate (Capla, Dormate) is an anxiolytic and sedative drug with antihypertensive effects of the carbamate class.[1][2] It has effects comparable to those of barbiturates such as secobarbital, but is only around 1/3 the potency of secobarbital as a sedative. Side effects include dizziness and headaches.[3]

Mebutamate is one of many GABAergic drugs which act via allosteric agonism of the GABAA receptor at the β-subreceptor similar to barbiturates. In contrast, benzodiazepines act at the α-subreceptor. As such, carbamates and barbiturates, possess analgesic properties while the benzodiazepine class of drugs are strictly psychoactive.

Other carbamates with the same mechanism of action and pharmacological properties include meprobamate, carisoprodol, felbamate, and tybamate.

Synthesis

Mebutamate synthesis: Berger, Ludwig, U.S. patent 2,878,280 (1959 to Carter Prod.).

Structural analogs

References

  1. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. p. 634. ISBN 978-3-88763-075-1.
  2. ^ The Merck Index (14 ed.). Merck Publishers. 2006-11-03. 5813. ISBN 978-0-911910-00-1.
  3. ^ Tetreault L, Richer P, Bordeleau JM (August 1967). "Hypnotic properties of mebutamate: a comparative study of mebutamate, secobarbital and placebo in psychiatric patients". Canadian Medical Association Journal. 97 (8): 395–8. PMC 1923261. PMID 6037393.
  • v
  • t
  • e
5-HT1ARTooltip 5-HT1A receptor agonistsGABAARTooltip GABAA receptor PAMsTooltip positive allosteric modulatorsHypnoticsGabapentinoids
(α2δ VDCC blockers)Antidepressants
AntipsychoticsSympatholytics
(Antiadrenergics)Others
  • v
  • t
  • e
GABAA receptor positive modulators
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Flavonoids
Imidazoles
Kava constituents
  • 10-Methoxyyangonin
  • 11-Methoxyyangonin
  • 11-Hydroxyyangonin
  • Desmethoxyyangonin
  • 11-Methoxy-12-hydroxydehydrokavain
  • 7,8-Dihydroyangonin
  • Kavain
  • 5-Hydroxykavain
  • 5,6-Dihydroyangonin
  • 7,8-Dihydrokavain
  • 5,6,7,8-Tetrahydroyangonin
  • 5,6-Dehydromethysticin
  • Methysticin
  • 7,8-Dihydromethysticin
  • Yangonin
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Pyrazolopyridines
Quinazolinones
Volatiles/gases
Others/unsorted
  • Unsorted benzodiazepine site positive modulators: α-Pinene
  • MRK-409 (MK-0343)
  • TCS-1105
  • TCS-1205
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators
Stub icon

This sedative-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e